# Somatuline Autogel: Acromegaly Self/Partner Injection Study

> **NCT00149188** · PHASE4 · COMPLETED · sponsor: **Ipsen** · enrollment: 30 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Lanreotide (Autogel formulation)

## Key facts

- **NCT ID:** NCT00149188
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2005-08-24
- **Final completion:** 2005-08-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00149188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00149188, "Somatuline Autogel: Acromegaly Self/Partner Injection Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00149188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*